Stratec stock reports a Q2 recovery as execution risks rise

Published on 10/03/2026 at 20:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stratec stock was last at EUR 21.70 on October 2, 2026, while Q2 adjusted EBIT rose 125.3 percent year over year. mwb research kept its EUR 21.00 target.

Bauhaus-Poster mit geometrischen Formen, Mikroskop-Symbol und Schriftzug MEDTECH — Stratec SE (DE000STRA555) prägt die Medizintechnik-Branche, dargestellt als geometrisches Bauhaus-Poster mit Laborsymbolik, Illustration mit AI erstellt.

Stratec stock (ISIN DE000STRA555) was last at EUR 21.70 on Xetra on October 2, 2026, up 0.23 percent from the previous session. The latest investment debate centers on a sharp Q2 recovery and the demanding execution required in the second half of 2026.

Q2 margin recovery stands out

According to ResearchHub in research dated September 17, 2026, Stratec generated Q2 2026 revenue of EUR 59.1 million, up 2.4 percent year over year at constant currency.

The improvement was more pronounced below the revenue line. Adjusted EBIT rose 125.3 percent year over year to EUR 7.0 million, lifting the adjusted EBIT margin to 11.9 percent; reported EBIT was EUR 5.4 million, with a 9.4 percent margin, according to the same September 17, 2026 research update.

Second half sets the test

ResearchHub's analysis says Stratec would need EUR 149 million to EUR 161 million of second-half revenue to meet its fiscal 2026 outlook. That implies 12 percent to 22 percent growth against the second half of 2025, making customer ordering patterns and fourth-quarter delivery the central operating variables.

The contrast is clear: Q2 adjusted EBIT advanced 125.3 percent, while constant-currency revenue grew 2.4 percent. The margin recovery is therefore doing more work than the top line, and the quality of recurring service and consumables demand remains important for the next report.

Analyst target stays below price

As FinanzNachrichten reported on September 17, 2026, mwb research downgraded Stratec from Hold to Sell and kept its price target at EUR 21.00. The firm cited volatile customer ordering and the demanding second-half requirement, putting the target below the EUR 21.70 Xetra price seen on October 2, 2026.

Stratec stock holds at EUR 21.70

Stratec stock was last at EUR 21.70 on Xetra at 5:35 p.m. CEST on October 2, 2026, with a daily gain of 0.23 percent. The company operates in laboratory automation and develops systems for in-vitro diagnostics and life science partners.